Trametinib
Lymphoproliferative Syndrome
Cancer Research UKSmall moleculePhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 89/ 100
Competitive context
26 Active assets in the Lymphoproliferative Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darbepoetin Alfa Mayo Clinic | Phase 3 | BB |
Epoetin Alfa Mayo Clinic | Phase 3 | BB |
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Baclofen Alliance for Clinical Trials in Oncology | Phase 3 | BB |
SODIUM FERRIC GLUCONATE Mayo Clinic | Phase 3 | BB |
View all 48 →
Same molecule, other indications
Trametinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →